Welcome to SOCIAL NEWS AI: Click here for the Ink Buddy AI E-book Generator

Beyond Anti-TNF: Is Ustekinumab a Better Choice in Crohn's?

TOPLINE: Ustekinumab exhibited higher persistence rates as a second-line therapy than anti–tumour necrosis factor (anti-TNF) treatment in patients with Crohn’s disease. Clinical remission rates with ustekinumab improved progressively, reaching 100% by 5 years. METHODOLOGY: Researchers conducted this retrospective observational study of a prospective database to compare the persistence rates of ustekinumab as a second-line treatment ...

Make Money Selling eBooks!

Make Money Selling e-books!

Get In Touch

New York, USA

413

info@example.com

Follow Us
Flickr Photos

Copyright © 2023 socialnews. All Rights Reserved